Hexagon Bio
Hexagon Bio is a Menlo Park, California biotechnology company developing novel payloads for antibody-drug conjugates (ADCs) in oncology. The company designs next-generation ADC payloads intended to overcome resistance to current payloads and to expand the range of cancer indications ADCs can treat. Backed by SoftBank Vision Fund, Hexagon Bio operates a therapeutics pipeline and research platform rather than a public developer program: it publishes no API, SDK, or developer documentation surface. This profile was surfaced as a portfolio-company lead and enriched from Hexagon Bio's own public website (company, pipeline, science/platform, and news pages).
Hexagon Bio is profiled on the APIs.io network. Tagged areas include Company, Health Tech, Biotechnology, Oncology, and Antibody-Drug Conjugates.
Hexagon Bio’s developer surface includes engineering blog and 2 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 2
The organization behind the API